The notices it replaced
- Reissues: PA-17-302 PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 2 steps back: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 3 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 4 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 5 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 6 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 10 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-19-272.
Who won it before
4,393 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,603,523,693 in first-year total cost, median $225,009.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]232
- Special Emphasis Panel[ZRG1 ETTN-G (12)]210
- Special Emphasis Panel[ZRG1 IMST-H (15)]159
- Special Emphasis Panel[ZRG1 IDM-V (12)]143
- Special Emphasis Panel[ZRG1 IMST-K (14)]131
Most frequent institutions
- PHYSICAL SCIENCES, INC29
- AFFINERGY, LLC28
- EPICYPHER, INC.28
- PANORAMA RESEARCH, INC.22
- LYNNTECH, INC.20
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Inhaled IRK inhibitors as a novel therapeutic for IPF1R44HL151067-01 | HAVA, DAVID L | METERA PHARMACEUTICALS, INC., MA | $1,515,600 | ZRG1 |
| 2020 | Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment1R44TR003162-01 | ABI GERGES, NAJAH | ANABIOS CORPORATION, CA | $1,132,289 | ZRG1 |
| 2020 | Paradigm Surgical Phase II-Development and Validation of SafeClose Roller Mesh Augmentation System for Hernia Treatment and Prevention2R44GM123789-02 | FISCHER, JOHN PATRICKPETERS, REX | PARADIGM SURGICAL, LLC, PA | $1,026,094 | ZRG1 |
| 2020 | Therapeutic UV Disinfection System to Prevent Catheter Related Bloodstream Infections (CRBSIs) in Patients with Peripherally Inserted Central Catheters (PICCs)2R44AI134553-02A1 | FOURKAS, MICHAELRASOOLY, JULIA | PURACATH MEDICAL, INC., CA | $1,000,000 | ZRG1 |
| 2020 | MucoCept-CVN, a genetically enhanced vaginal Lactobacillus strain for the prevention of HIV acquisition in women: Finalization of formulation for the first-in-human clinical trial1R44AI149807-01 | LAGENAUR, LAUREL A. | OSEL, INC., CA | $1,000,000 | ZRG1 |
| 2020 | Therapy and Prophylaxis for Genital Tract Infection2R44AI104067-04A1 | AUCI, DOMINICKRUSSELL, MICHAEL W | THERAPYX, INC., NY | $1,000,000 | ZRG1 |
| 2020 | A Once-Weekly Oral Tacrolimus-Prednisone Fixed-Dose Combination Therapy for Post-Transplant Maintenance Immunosuppressive Therapy1R44AI149979-01 | ZALE, STEPHEN | LYNDRA THERAPEUTICS, INC., MA | $1,000,000 | ZRG1 |
| 2020 | Third line treatment of drug resistant FLT3-positive acute myeloid leukemia with a novel FLT3 kinase inhibitor1R44CA247134-01 | HOLTSBERG, FREDERICK WAYNESINTIM, HERMAN O | KINARX, LLC, MD | $1,000,000 | ZRG1 |
| 2020 | Bloodstream infection detection directly on whole blood2R44AI124871-02A1 | CELEDON, ALFREDO ANDRES | SCANOGEN, INC., MD | $1,000,000 | ZRG1 |
| 2020 | Pre-IND Development of an Arenavirus Antiviral2R44AI112097-05 | HENKEL, GREGORY WILLIAM | ARISAN THERAPEUTICS, INC., CA | $1,000,000 | ZRG1 |
| 2020 | Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling1R44GM136083-01 | MAKAROV, SERGEI S | ATTAGENE, INC., NC | $999,998 | ZRG1 |
| 2020 | Cryopreservation of Anopheles Embryos2R44AI088853-06 | BILLINGSLEY, PETER F. | SANARIA, INC., MD | $999,997 | ZRG1 |
| 2020 | Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy2R44AI125060-02 | EBETINO, FRANK H. | BIOVINC, LLC, CA | $999,300 | ZRG1 |
| 2020 | Commercialization of a highly-sensitive, scalable and low-input compatible kit-based solution for discovery of translocations from FFPE tumor biopsies1R44CA247185-01 | SELVARAJ, SIDDARTH | ARIMA GENOMICS, INC., CA | $999,273 | ZRG1 |
| 2020 | Strain-Independent Therapeutic Antibodies for Influenza2R44AI106077-05 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $999,214 | ZRG1 |
| 2020 | Biofilm disrupting antibody to treat respiratory and musculoskeletal infections1R44AI150143-01 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $999,192 | ZRG1 |
| 2020 | In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV2R44AI138728-02 | CONE, RICHARD | MUCOMMUNE, LLC, NC | $999,032 | ZRG1 |
| 2020 | An H/F/X/Y Fast-MAS NMR Probe Particularly for Alzheimer's and Cancer Research2R44GM119937-02 | DOTY, FRANCIS DAVID | DOTY SCIENTIFIC, INC., SC | $997,231 | ZRG1 |
| 2020 | Rapid quantification of nuclear citrullination in human neutrophils2R44AI134162-02 | JOHNSTONE, ANDREA LYNN | EPICYPHER, INC., NC | $993,542 | ZRG1 |
| 2020 | Kinase Targeted Antimalarial Agents1R44AI150237-01 | ZUTSHI, REENA | LUCEOME BIOTECHNOLOGIES, LLC, AZ | $957,654 | ZRG1 |
| 2020 | Myocardial Delivery of MMP Inhibiting Hydrogels2R44HL140645-02 | PURCELL, BRENDAN | PROHIBIX, LLC, PA | $954,900 | ZRG1 |
| 2020 | Oral PCSK9/LDLR antagonist direction to the clinic1R44HL150923-01 | ELSHOURBAGY, NABIL AMOUSA, SHAKER A | SHIFA BIOMEDICAL CORPORATION, PA | $943,895 | ZRG1 |
| 2020 | Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines2R44AI131742-02 | HARDING, CHRISTIAN | VAXNEWMO, LLC, MO | $931,060 | ZRG1 |
| 2020 | Multiplex nucleosome-based profiling for the development of next-generation chromatin labeling reagents1R44GM136172-01 | SUN, ZU-WEN | EPICYPHER, INC., NC | $920,218 | ZRG1 |
| 2020 | Quantitative and highly versatile chromatin accessibility platform1R44HG011006-01 | KEOGH, MICHAEL-CHRISTOPHER | EPICYPHER, INC., NC | $910,411 | ZRG1 |
| 2020 | Portable Ultrasound System for Automated Detection of Abdominal Free-Fluid2R44GM123821-02 | FELDMAN, JAMES ALANVAZIRI, ASHKAN | BIOSENSICS, LLC, MA | $818,052 | ZRG1 |
| 2020 | New infusible ECM hydrogel for treating acute myocardial infarction1R43HL150917-01 | CHRISTMAN, KAREN LKINSEY, ADAM M | VENTRIX, INC., CA | $791,543 | ZRG1 |
| 2020 | Feasibility and validation of an integrated newborn screening algorithm with targeted Next Generation Sequencing (tNGS) technology as part of a 2nd-tier test for Pompe and MPS I2R44HD094543-02 | BHATTACHARJEE, ARINDAM | BAEBIES, INC., NC | $778,727 | ZRG1 |
| 2020 | Novel strategies for storage and recovery of cadaveric bone marrow stem cells2R44HL142418-02 | WOODS, ERIK J. | OSSIUM HEALTH, INC., CA | $778,661 | ZRG1 |
| 2020 | Sinu-Test, A Multiplexed Device for Rapid Diagnosis of Acute Bacterial Sinusitis1R44AI150203-01 | HAWKINS, ORIANA E. | ENTVANTAGE DX, TX | $762,667 | ZRG1 |
| 2020 | PROTECT: optima4BP 2.0: prediction of Optimal Treatment and Route to achieve and maintain BP Target2R44HL140624-02 | VOSKERICIAN, GABRIELA | OPTIMA INTEGRATED HEALTH, INC., CA | $750,249 | ZRG1 |
| 2020 | FVIII Point-of-Care Monitoring Device and App1R44HL151147-01 | CHAN, EUGENE YAN-HO | DNA MEDICINE INSTITUTE, MA | $749,250 | ZRG1 |
| 2020 | Digital representation of chemical mixtures to aid drug discovery and formulation2R44TR002528-02 | BUNIN, BARRY A | COLLABORATIVE DRUG DISCOVERY, INC., CA | $748,733 | ZRG1 |
| 2020 | An Integrated Software Platform for Accelerating Image-Driven Ophthalmic Research and Driving New Insights and Endpoints to the Clinic1R44EY031198-01 | BUCKLAND, ERIC L. | TRANSLATIONAL IMAGING INNOVATIONS, INC., NC | $743,347 | ZRG1 |
| 2020 | Directed evolution of N-terminal amino acid binding proteins for application to protein sequencing2R44GM123836-02A1 | KUHN, KENNETH M | ENCODIA, INC., CA | $736,945 | ZRG1 |
| 2020 | Validating Automated Photoreceptor Analytics Software For Degenerative Eye Disease Research and Biopharma Clinical Trials.1R44EY031278-01 | BUCKLAND, ERIC L.CARROLL, JOSEPH | TRANSLATIONAL IMAGING INNOVATIONS, INC., NC | $726,590 | ZRG1 |
| 2020 | Advancing CAP4196 into in vivo Proof of Concept Translational Studies2R44EY027236-03 | PRASAD, SRIDHAR G | PLEX PHARMACEUTICALS, INC., CA | $662,896 | ZRG1 |
| 2020 | IOPSxV: Novel Visualization for Non-Fluoroscopic 3D Image Guidance for Peripheral Vascular Interventions.1R44HL151148-01 | GOEL, VIKASH | CENTERLINE BIOMEDICAL, INC., OH | $636,861 | ZRG1 |
| 2020 | A proximity ligation method to track mobile element hosts1R44AI150008-01 | LIACHKO, IVAN | PHASE GENOMICS, INC., WA | $599,017 | ZRG1 |
| 2020 | Development of Kv1.3 Monoclonal Antibodies Targeting TEM Cells for Treating Autoimmune Disorders2R44GM112181-03 | RUCKER, JOSEPH BENJAMIN | INTEGRAL MOLECULAR, PA | $585,859 | ZRG1 |
| 2020 | Rapid Test Kit for Measurement of Urinary Iodine2R44HD095689-02 | VAIDYA, BIKAS | LYNNTECH, INC., TX | $538,447 | ZRG1 |
| 2020 | Novel Low Temperature Sterilization Method for Flexible Endoscopes2R44AI122405-02A1 | WILLIAMS, JOEL L | BRIGHTON DEVELOPMENT, LLC, NC | $521,870 | ZRG1 |
| 2020 | CHABMAP (Cyanobacterial Harmful Algal Bloom Mapping and Analyses Platform) technology automates the quantification of toxic CyanoHABs exposure epochs for any waterbody.2R44ES025513-02A1 | TORBICK, NATHAN | APPLIED GEOSOLUTIONS, LLC, NH | $504,200 | ZRG1 |
| 2020 | FoxWare™, An Advanced Data Analysis Package for Hydroxyl Radical Foot-Printing Higher Order Structural Analysis2R44GM126617-02 | WEINBERGER, SCOT RANDY | GENNEXT TECHNOLOGIES, INC., CA | $477,220 | ZRG1 |
| 2020 | Enhancing Pediatric Diagnosis of Tuberculosis with FLOW Technology1R44HD101201-01 | BERRY, SCOTT MMULLINS, BRIANNAWARRICK, JAY WYATT | SALUS DISCOVERY, LLC, WI | $436,366 | ZRG1 |
| 2020 | Circulating Organ-enriched microRNAs as biomarkers of Rett Syndrome1R43NS115212-01 | UMANSKY, SAMUIL R | DIAMIR, LLC, NJ | $387,616 | ZRG1 |
| 2020 | Phosphosulindac for dry eye1R44EY031193-01 | RIGAS, BASIL | APIS THERAPEUTICS, LLC, NY | $377,136 | ZRG1 |
| 2020 | Multi-gram enzymatic production of complex glycans by flow processes1R44GM136085-01 | HOEPKER, ALEXANDER CHRIS | ZYMTRONIX CATALYTIC SYSTEMS, INC., NY | $354,457 | ZRG1 |
| 2020 | Platelet Production in a Pulmonary-based Microfluidic Reactor1R43HL150946-01 | YEHIA, ALI | FLUXION BIOSCIENCES, INC., CA | $308,559 | ZRG1 |
| 2020 | Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis1R43AI149833-01 | HANNAN, THOMAS JOSEPH | FIMBRION THERAPEUTICS, INC., MO | $300,000 | ZRG1 |
| 2020 | Discovery of Treponema pallidum antigens for development of a sensitive and specific diagnostic test for syphilis1R43AI149804-01 | CAMPO, JOSEPH J. | IMMPORT THERAPEUTICS, INC., CA | $300,000 | ZRG1 |
| 2020 | Discovery of Enterovirus D68 2A protease inhibitors for antiviral therapy1R43AI149822-01 | LIU, GAI | MICROBIOTIX, INC, MA | $300,000 | ZRG1 |
| 2020 | Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health Threats1R43AI145617-01A1 | PRASAD, SRIDHAR G | PLEX PHARMACEUTICALS, INC., CA | $300,000 | ZRG1 |
| 2020 | Development of Intact Proviral DNA Assays for SIV and SHIV1R43AI149816-01 | LAIRD, GREGORY MICHAEL | ACCELEVIR DIAGNOSTICS, LLC, MD | $300,000 | ZRG1 |
| 2020 | A Novel Probiotic-Based Nanobody Delivery Platform1R43AI149906-01 | FANGER, NEIL A | VIRTICI, LLC, WA | $300,000 | ZRG1 |
| 2020 | Production and Testing of VLP-based RSV Vaccine1R43AI145499-01A1 | GALARZA, JOSE M. | TECHNOVAX, INC., NY | $300,000 | ZRG1 |
| 2020 | Ice-free cryopreservation of whole pediatric testes for autologous banking and replantation.1R43HD101325-01 | BROCKBANK, KELVIN G.M. | TISSUE TESTING TECHNOLOGIES, LLC, SC | $300,000 | ZRG1 |
| 2020 | Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients1R43AI149903-01 | LEVIN, ANDREW E. | KEPHERA DIAGNOSTICS, LLC, MA | $299,998 | ZRG1 |
| 2020 | Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease1R43HL150961-01 | BURNETT, JAMES | ILLEXCOR THERAPEUTICS, LLC, VA | $299,962 | ZRG1 |
| 2020 | An Improved Intra-Arterial Delivery Platform for Glioblastoma Multiforme1R43CA239945-01A1 | CREIGHTON, FRANCIS MILTONGREENSPAN, DAVID C | UNANDUP, LLC, MO | $299,946 | ZRG1 |
| 2020 | Engineering a Potent Immune-evading Uricase1R43AI149839-01 | BAILEY-KELLOGG, CHRIS | STEALTH BIOLOGICS, LLC, NH | $299,870 | ZRG1 |
| 2020 | Algorithms to Detect In-Home Falls of Elderly Using Structured Light Sensing1R43AG066263-01 | GIBSON, PAUL | APPLIED UNIVERSAL DYNAMICS CORPORATION, MN | $299,824 | ZRG1 |
| 2020 | Immunoprofiling to develop a novel diagnostic array for cardiac sarcoidosis1R43HL150911-01 | DARBY, MARTYN | AFFINERGY, LLC, NC | $299,802 | ZRG1 |
| 2020 | Development of a peptide-based diagnostic for amyotrophic lateral sclerosis1R43NS115201-01 | NAIR, SHRIKUMAR AMBUJAKSHAN | AFFINERGY, LLC, NC | $299,778 | ZRG1 |
| 2020 | Development of a Mucosal Nanoemulsion-Adjuvanted RSV Vaccine using Recombinant Pre-Fusion F Protein1R44AI145431-01A1 | BITKO, VIRA | BLUEWILLOW BIOLOGICS, INC., MI | $299,650 | ZRG1 |
| 2020 | A High Sensitivity Multiplexed Immunoassay for Aging-Related Inflammation Biomarker Quantification1R43AG066380-01 | CRICK, SCOTT L | AURAGENT BIOSCIENCE, LLC, MO | $299,578 | ZRG1 |
| 2020 | Mitral Valve Repair System to Percutaneously Treat Moderate to Severe Regurgitation Using Alfieri Edge-to-Edge Technique1R43HL147825-01A1 | BASUDE, RAGHUVEER | MEDFREE, INC., CA | $299,413 | ZRG1 |
| 2020 | Deimmunized Griffithsin Microbicide1R44AI150235-01 | BAILEY-KELLOGG, CHRIS | STEALTH BIOLOGICS, LLC, NH | $299,275 | ZRG1 |
| 2020 | Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections1R43HL147749-01A1 | REED, MATTHEW | NOB HILL THERAPEUTICS, INC., NM | $299,058 | ZRG1 |
| 2020 | Improving gene expression via Massively Parallel Synonymous Codon Variant Screening1R43GM135955-01 | WYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $298,634 | ZRG1 |
| 2020 | Dynamic Breath Gas Sensor (DBGS™) for Detection of Pulmonary Edema1R43HL150884-01 | SHEKARRIZ, REZA | EXHALIX, LLC, NM | $298,273 | ZRG1 |
| 2020 | Evaluation of the Effect of Commercial Processing on Artificial Lung Zwitterionic Coatings1R43HL150977-01 | SKOOG, DAVID | ADVANCED RESPIRATORY TECHNOLOGIES, LLC, PA | $298,100 | ZRG1 |
| 2020 | Degradable hydrogel for retinal tamponade (phase 2)2R44EY027635-02A1 | BRAITHWAITE, GAVIN JAMES | CAMBRIDGE POLYMER GROUP, INC., MA | $296,103 | ZRG1 |
| 2020 | Safety and efficacy of an allergy therapeutic targeting FcERI bound IgE in human immune reconstituted mice.1R43AI149739-01 | SAXON, ANDREW | SIXAL CORPORATION, CA | $286,656 | ZRG1 |
| 2020 | Novel Dual Acting Antibiotics for Pulmonary Disease1R43AI145766-01A1 | DONN, KARL H | PARION SCIENCES, INC., NC | $274,173 | ZRG1 |
| 2020 | Detection of fetal platelets in maternal blood using platelet RNA biomarkers.1R43HL147793-01A1 | GNATENKO, DMITRI V | BLOOD CELL TECHNOLOGIES, LLC, NY | $272,302 | ZRG1 |
| 2020 | MosaicVillage: A Youth-Informed Platform to Reduce Youth Homelessness Through Collective Impact1R43HD099003-01A1 | CEARLEY, JENNIFER JOYWENDT, ADAM JOHN | IRIS MEDIA, INC., OR | $262,499 | ZRG1 |
| 2020 | Targeted Exosome-Associated AAV-Mediated Gene Therapy to Eliminate Metastatic Neuroendocrine Cancers1R43CA246883-01 | GARNER, JOSEPH NLIU, XIAOGUANG MARGARETWHITT, JASON DEREK | TECHNOLOGY COMMERCIALIZATION PARTNERS, LLC, AL | $243,144 | ZRG1 |
| 2020 | Super-sensitive detection of universal markers of allograft rejection1R43AI150530-01 | MURRAY, JAMES L | GENETAG TECHNOLOGY, INC., GA | $242,610 | ZRG1 |
| 2020 | Targeting ALS-linked FUS with allele-specific antisense oligonucleotides1R43NS115350-01 | GERBER, DAVID JULIANWILLIAMS, LUIS ALBERTO | Q-STATE BIOSCIENCES, INC., MA | $236,911 | ZRG1 |
| 2020 | A Web Service for Fragment-based Selectivity Analysis of Drug Leads1R43GM133284-01A1 | KULP III, JOHN LAURENCE | CONIFER POINT PHARMACEUTICALS, LLC, PA | $234,737 | ZRG1 |
| 2020 | Ultra-Sensitive Vapor Phase Hydrogen Peroxide Sensor for Decontaminating Pharmaceutical Manufacturing Facilities and Equipment1R43GM135957-01 | BRUMFIELD, BRIAN E | PHYSICAL SCIENCES, INC, MA | $231,250 | ZRG1 |
| 2020 | Biological Equivalence of In Vitro Plasmodium falciparum Culture for Practical Malaria Vaccine Development1R43AI149889-01 | AVRIL, MARIONWILDER, BRANDON KEITH | MALARVX, INC., WA | $230,288 | ZRG1 |
| 2020 | Optical probe for in situ assessment of pulmonary fibrosis1R43HL150948-01 | IFTIMIA, NICUSOR | PHYSICAL SCIENCES, INC, MA | $229,963 | ZRG1 |
| 2020 | A Rapid Multiplexed Test for the Screening of Sepsis and Organ Dysfunction at the Point of Care1R43GM135985-01 | DESA, JOHANN | INSTADIAGNOSTICS, INC., PA | $225,000 | ZRG1 |
| 2020 | Predictive assessment of acute and chronic cardiotoxicity using combinatorially matured hPSC-CMs1R44HL151094-01 | GEISSE, NICHOLAS ANDREW | CURI BIO INC, WA | $225,000 | ZRG1 |
| 2020 | Anti-angiogenic gene therapy of ocular vascular diseases1R43EY031238-01 | LI, WEITIAN, HONGWEBSTER, KEITH A | EVERGLADES BIOPHARMA, LLC, TX | $225,000 | ZRG1 |
| 2020 | Fully modified bispecific aptamer for effective combination therapy of neovascular ocular diseases1R44EY030822-01A1 | GONG, QIANG | APTITUDE MEDICAL SYSTEMS, INC., CA | $224,973 | ZRG1 |
| 2020 | Safety-Enhancing Motor Vehicle Child Safety Seat1R43HD101139-01 | RYDBERG, NICK | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $224,953 | ZRG1 |
| 2020 | Novel anti-fibrotic therapy for IPF1R43HL150897-01 | LARRICK, JAMES WYU, BO | LARIX BIOSCIENCE, LLC, CA | $224,924 | ZRG1 |
| 2020 | Targeted Gene Insertion by Directed Evolution of ΦC31 Integrase for Therapeutic Gene Editing1R44GM136045-01 | CHEN-TSAI, RUBY YANRU | APPLIED STEMCELL, INC., CA | $224,854 | ZRG1 |
| 2020 | Multiplexed wireless battery-free sensors for pediatric intensive care units (PICU).1R43HD101189-01 | MODEL, JEFFREY | WEARIFI, INC., IL | $224,821 | ZRG1 |
| 2020 | Continuous Non-Invasive Blood Pressure Monitor for Neonates1R43HD101175-01 | QUAN, XINA | PYRAMES, INC., CA | $224,556 | ZRG1 |
| 2020 | Cell-based assay directly monitoring viral polymerase activity for drug discovery.1R43AI150006-01 | O'HANLON, RYAN | LUCERNA, INC., NY | $224,323 | ZRG1 |
| 2020 | Feasibility Testing of a Microphone System to Facilitate Patient Communication During Noninvasive Ventilation1R43HL147788-01A1 | BREWER, LARA M | AXON MEDICAL, INC., UT | $224,225 | ZRG1 |
| 2020 | Temperature-Responsive Clips for Removable Dental Prostheses1R43DE028777-01A1 | SEO, YOUNG | RODO MEDICAL, INC., CA | $223,891 | ZRG1 |
| 2020 | Computer-Aided Decision Support System for Catheter-Based Pulmonary Valve Replacement1R43HL147747-01A1 | ARIKATLA, VENKATA SREEKANTH | KITWARE, INC., NY | $223,020 | ZRG1 |
| 2020 | A New Superconducting Detector Technology for Mass Spectrometry of Large Biomolecules1R43GM135959-01 | KELLY, THOMAS FRED | STEAM INSTRUMENTS, INC., WI | $221,263 | ZRG1 |
| 2020 | CDK2 inhibitors for protecting hearing loss1R43DC018463-01 | ZALLOCCHI, MARISA L. | TING THERAPEUTICS, INC., CA | $220,653 | ZRG1 |
| 2020 | Light engineering module for fast high-resolution whole-cell imaging1R43EB028726-01A1 | COLOMB, WARREN | DOUBLE HELIX OPTICS INC., CO | $218,223 | ZRG1 |
| 2020 | Targeting Neutrophil Extracellular Traps for Acute Lung Injury1R43HL150944-01 | FUCHS, TOBIAS | NEUTROLIS, INC., MA | $209,500 | ZRG1 |
| 2020 | A PULSED CONDENSATION PARTICLE COUNTER FOR LOW-COST MONITORING OF ULTRAFINE AIRBORNE PARTICLES1R43ES031458-01 | HERING, SUSANNE VERA | AEROSOL DYNAMICS, INC., CA | $180,958 | ZRG1 |
| 2020 | AI platform for microscopy image restoration and virtual staining1U44GM136091-01 | LEE, SHIH-JONG J | DRVISION TECHNOLOGIES, LLC, WA | $172,359 | ZRG1 |
| 2020 | Encapsulated Silver Diamine Fluoride (E-SDF)1R43DE028762-01A1 | MILGROM, PETER M | ADP SILVER DENTAL ARREST, LLC, OR | $162,464 | ZRG1 |
| 2020 | Fiber adsorbent for remediation of multisolute contamination in drinking water.1R43ES031443-01 | TSUKAMOTO, TAKUJI | CHEMICA TECHNOLOGIES, INC., OR | $159,012 | ZRG1 |
| 2020 | High-stability solid-state cooled Cryo-TEM transfer holder1R43GM135954-01 | ALSEM, DAAN HEIN | HUMMINGBIRD PRECISION MACHINE COMPANY, WA | $150,000 | ZRG1 |
| 2020 | Reducing the prohibitive costs of protein production for therapeutic development1R43GM136097-01 | SHEPHERD, RYAN W. | PHYLLOTECH, LLC, WI | $150,000 | ZRG1 |
| 2020 | Ultra-low Fouling and Nitric Oxide Releasing Intravascular Catheters for Prevention of Thrombosis and Infection1R43HL149595-01A1 | HOPKINS, SEAN | INNOVETA BIOMEDICAL LLC, GA | $149,848 | ZRG1 |
| 2019 | Human Neural Cell Exosomes as a therapeutic treatment for stroke2R44NS103596-02 | BAKER, EMILY W | ARUNA BIOMEDICAL, INC., GA | $2,880,097 | ZRG1 |
| 2019 | A Single Dose Long-Acting Non-Addictive Polymer Conjugate Formulation of Buprenorphine that Provides Immediate and Prolonged Analgesia for Post-Operative Pain1R44NS115196-01 | MOREADITH, RANDALL WVIEGAS, TACEY XAVIER | SERINA THERAPEUTICS, INC., AL | $1,658,634 | ZRG1 |
| 2019 | Peripherally-Restricted Long-Acting Somatostatin Receptor 4 (LA-SSTR4) Agonists for Pain2R44DA045410-02 | RIVIERE, PIERRE | PEPTIDE LOGIC, LLC, CA | $1,585,395 | ZRG1 |
| 2019 | Catheter for Large Volume Intraparenchymal Brain Therapies2R44NS084701-03A1 | ABRAMOV, VASILIY | CREOSALUS, INC., KY | $1,493,724 | ZRG1 |
| 2019 | CTRA Software Solution for Fracture Risk Assessment of Axial Skeleton1R44AG065014-01 | NAZARIAN, ARAVAZIRI, ASHKANYASZEMSKI, MICHAEL J | BIOSENSICS, LLC, MA | $1,490,863 | ZRG1 |
| 2019 | A gel patch for replacing surgical eardrum repair with an office-based procedure1R44DC018255-01 | HORN-RANNEY, ELAINE LARKIE | TYMPANOGEN, LLC, VA | $1,479,163 | ZRG1 |
| 2019 | Completion of IND-package for a novel, non-narcotic painkiller2R44DA041912-03 · under PA-17-302 | YEKKIRALA, AJAY S | BLUE THERAPEUTICS, INC., MA | $1,474,091 | ZRG1 |
| 2019 | Software for OCT Analysis of Vascular Stents2R44HL137500-02 | SHALEV, RONNY | DYAD MEDICAL, INC., MA | $1,265,906 | ZRG1 |
| 2019 | System and comprehensive approach for blood compatibility of medical devices and biomaterial2R44HL131338-02 | CAHALAN, PATRICK THOMAS | ENSION, INC., PA | $1,261,442 | ZRG1 |
| 2019 | Development of a New Carbohydrate-based Anticoagulant Drug2R44HL139187-02 | PAGADALA, VIJAYAKANTH | GLYCAN THERAPEUTICS CORPORATION, NC | $1,244,412 | ZRG1 |
| 2019 | Preclinical Oxygen Imager to Model Efficient Cancer Treatment2R44CA224840-02 | KOTECHA, MRIGNAYANI | O2M TECHNOLOGIES, LLC, IL | $1,168,365 | ZRG1 |
| 2019 | Tailoring the Hydroxyl Radical Foot-Printing Approach to Provide a Solution for the Higher Order Structural Analysis Needs of the Biopharmaceutical Industry2R44GM125420-02 | WEINBERGER, SCOT RANDY | GENNEXT TECHNOLOGIES, INC., CA | $1,134,434 | ZRG1 |
| 2019 | Perfusion decellularization and recellularization for the creation of a bioengineered transplantable liver1R44DK122894-01A1 | ROSS, JEFFREY JAMES | MIROMATRIX MEDICAL, INC., MN | $1,129,548 | ZRG1 |
| 2019 | A Platform for Safe, Noninvasive Prenatal Genetic Testing at Five Weeks of Pregnancy2R44HD092205-02 | ARMANT, DAVID RANDALLGLIGORICH, KEITH MICHAEL | CRADLE GENOMICS, INC., CA | $1,098,375 | ZRG1 |
| 2019 | Translational feasibility of an oral, non-hormonal, male contraceptive pill1R44HD100256-01 | CROWE, PAUL D | ORPHAGEN PHARMACEUTICALS, CA | $1,093,784 | ZRG1 |
| 2019 | Performance Evaluation of a non-Degradable Synthetic Device for Chondral and Osteochondral Defects of the Knee2R44AR067533-02A1 | CHEN, TONY | HYDRO-GEN, LLC, NJ | $1,090,977 | ZRG1 |
| 2019 | Phase II: Development of a Neurovascular Magnetic Particle Imaging system with sub-millimeter resolution and real time speed for non-radiative 3D perfusion angiography2R44DA041814-02 | GOODWILL, PATRICKWINTERMARK, MAX | MAGNETIC INSIGHT, INC., CA | $1,066,136 | ZRG1 |
| 2019 | Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma2R44CA217489-03 | WANG, YEN TUN | CUREBIOTECH, INC., PA | $1,024,973 | ZRG1 |
| 2019 | Humanization, Production, and PK/PD Characterization of anti-TIP1 antibody against Non-Small Cell Lung Cancer2R44CA210687-02A1 | DEORE, SAPNA | MEDICAL GUIDANCE SYSTEMS, LLC, MO | $1,011,611 | ZRG1 |
| 2019 | Predevelopment of VV2003, a Novel CRAC Channel Inhibitor, to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy2R44CA224454-02 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $1,004,278 | ZRG1 |
| 2019 | Measureable Residual Disease testing for acute myeloid leukemia with single-cell genotyping1R44CA247135-01 | RUFF, DAVID W | MISSION BIO, INC., CA | $1,000,002 | ZRG1 |
| 2019 | Therapeutic Antibody for RSV IIB2R44AI122360-03 | KAUVAR, LAWRENCE MICHAEL | TRELLIS BIOSCIENCE, INC., CA | $1,000,000 | ZRG1 |
| 2019 | An automated platform for direct-from-specimen identification of pathogens common in endocarditis2R44AI136064-02 | SINGER, ALON | HELIXBIND, INC., MA | $1,000,000 | ZRG1 |
| 2019 | Development of VLP vaccine for RSV2R44AI109926-04A1 | BLANCO, JORGE C | SIGMOVIR BIOSYSTEMS, INC., MD | $1,000,000 | ZRG1 |
| 2019 | Development of GPER Agonists as Cancer Therapeutics2R44CA228695-02 | GARYANTES, TINA | LINNAEUS THERAPEUTICS, LLC, PA | $1,000,000 | ZRG1 |
| 2019 | Advancement of antiviral inhibitors of chikungunya virus2R44AI118115-03 | PEVEAR, DANIEL C | VENATORX PHARMACEUTICALS, INC., PA | $1,000,000 | ZRG1 |
| 2019 | Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain2R44AI094823-04A1 | BLATTNER, FREDERICK RLANDRY, CHARLES F | SCARAB GENOMICS, LLC, WI | $1,000,000 | ZRG1 |
| 2019 | New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry2R44AI112302-04A1 | MACNEVIN, CHRISTOPHER J | NIRVANA SCIENCES, INC., NC | $1,000,000 | ZRG1 |
| 2019 | Development of a Highly Sensitive Quantitative Rapid Digital LSPR Diagnostic for Acute Dengue and Zika Virus Infection2R44AI127055-02A1 | GERION, DANIELEHENKEL, GREGORY WILLIAM | ARISAN THERAPEUTICS, INC., CA | $1,000,000 | ZRG1 |
| 2019 | Optically Sensorized, Actuated Needles for Oncological Applications1R44CA243925-01 | MOSLEHI, BEHZAD | INTELLIGENT FIBER OPTIC SYSTEMS CORP, CA | $1,000,000 | ZRG1 |
| 2019 | IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy2R44AI124815-02A1 | SMITH, THOMAS J. | AURITEC PHARMACEUTICALS, INC., CA | $999,998 | ZRG1 |
| 2019 | Development and Validation of a Collaborative Web/Cloud-Based Dosimetry System for Radiopharmaceutical Therapy.2R44CA213782-02 | FREY, ERIC C.GHALY, MICHAEL | RADIOPHARMACEUTICAL IMAGING AND DOSIMETRY, LLC, MD | $999,998 | ZRG1 |
| 2019 | A single antiviral to treat multiple opportunistic infections2R44AI114079-02 | REMISZEWSKI, STACY | EVRYS BIO, LLC, PA | $999,997 | ZRG1 |
| 2019 | Multiplex Platform for Point-of-Care Newborn Screening of Hyperbilirubinemia2R44HD072853-06 | PAMULA, VAMSEE K. | BAEBIES, INC., NC | $999,995 | ZRG1 |
| 2019 | Preclinical development of Novo29, a new antibiotic2R44AI136137-02A1 | LING, LOSEE LUCY | NOVOBIOTIC PHARMACEUTICALS, LLC, MA | $999,992 | ZRG1 |
| 2019 | Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs2R44AI100339-05 | BUTLER, MICHELLE M. | MICROBIOTIX, INC, MA | $999,986 | ZRG1 |
| 2019 | A Multiscale Simulation Toolkit for Computational Pharmacology of Trans/Intradermally Administered Compounds in Healthy and Diseased Population2R44FD005345-02 | GARIMELLA, HARSHA TEJA | CFD RESEARCH CORPORATION, AL | $999,921 | ZRG1 |
| 2019 | Rapid, Point-of-Care Nucleic Acid Test for HCV1R44DK123849-01 | CHO, HYUNDAE | CROSSLIFE TECHNOLOGIES, INC., CA | $999,841 | ZRG1 |
| 2019 | System for faster microarray assays and end-to-end workflow automation2R44GM122159-02A1 | FISHER, JAY KENNETH | REDBUD LABS, INC., NC | $999,735 | ZRG1 |
| 2019 | Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis2R44AI098271-06 | BUTLER, MICHELLE M. | MICROBIOTIX, INC, MA | $999,559 | ZRG1 |
| 2019 | Radiation Sterilizable, RFID Tagged Vials for Biomedical Samples2R44OD020162-04 · under PA-17-302 | DAVIDOWITZ, HANANEL | BIO TILLION, LLC, NJ | $999,504 | ZRG1 |
| 2019 | Continuing Preclinical Development of PPCM Vaginal Contraceptive MPT to IND2R44HD092206-03 | JERSE, ANN E.NORTH, BARBARA BESTWALLER, DONALD PWEITZEL, MARY B | YASO THERAPEUTICS INC, TX | $999,102 | ZRG1 |
| 2019 | Stream Dx: Point of Care Cellular Enabled IoT Communication Hub for Improved Diagnosis, Monitoring, and Post-Treatment Evaluation of LUTS2R44DK113878-03 | HOTALING, JAMESMCCLELLAN, SCOTT BRADFORD | STREAM DX, INC., UT | $998,995 | ZRG1 |
| 2019 | Microneedle Delivery of Zanamivir for Treatment of Influenza2R44AI129122-03A1 | LIPKA, ELKE | TSRL, INC., MI | $998,654 | ZRG1 |
| 2019 | Uterine Wall-Membrane Anchor Device for the Prevention of Preterm Premature Rupture of the Membranes Following Fetoscopic Surgery2R44HD094456-02 | VARADHACHARY, ATUL | FANNIN PARTNERS, LLC, TX | $998,650 | ZRG1 |
| 2019 | Development of a Balloon Occlusion Sheath for Stroke (BOSS)2R44NS103670-02 | HATCHER, BRADYKALLMES, DAVID F | MARBLEHEAD MEDICAL, LLC, MN | $998,169 | ZRG1 |
| 2019 | A computational platform to improve the prioritization of drugs and target genes for therapeutic intervention2R44TR002035-02 | MCGARY, KRISTON LYLE | GENETIC NETWORKS, LLC, FL | $991,290 | ZRG1 |
| 2019 | Medical Device Cyber-Security2R44GM126614-02 | UPLINGER, JAMES | NOKOMIS, INC., PA | $990,726 | ZRG1 |
| 2019 | Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database2R44GM117961-04A1 | OLAFSON, BARRY D | PROTABIT, LLC, CA | $990,318 | ZRG1 |
| 2019 | Optimization of novel pyranopyridine efflux pump inhibitors2R44AI100332-06 | OPPERMAN, TIMOTHY J. | MICROBIOTIX, INC, MA | $987,681 | ZRG1 |
| 2019 | Sensitive and Portable Physician Office-Based Urine Analyzer to Tackle Prescription Drug Abuse2R44DA043325-02 | HEFFERNAN, MICHAEL JOHN | BREVITEST TECHNOLOGIES, INC., TX | $986,127 | ZRG1 |
| 2019 | Treating Peritoneal Malignancies with Paclitaxel-Loaded Expansile Nanoparticles2R44CA189215-02A1 | COLBY, AARON HENRY | IONIC PHARMACEUTICALS, MA | $982,798 | ZRG1 |
| 2019 | IND-enabling assay validation and toxicology studies on AKS-107: a novel antigen-specific B cell therapeutic to prevent Type 1 Diabetes2R44DK107099-04 | ZION, TODD C | AKSTON BIOSCIENCES CORPORATION, MA | $978,643 | ZRG1 |
| 2019 | Novel enzyme inhibitor screening platform using modified designer nucleosomes2R44GM119893-02A1 | SUN, ZU-WEN | EPICYPHER, INC., NC | $968,299 | ZRG1 |
| 2019 | Rapid and Effective Localized Neurovascular Cooling Using the Khione Insulative Catheter2R44NS095573-03A1 | MERRILL, THOMAS L | FOCALCOOL, LLC, NJ | $967,506 | ZRG1 |
| 2019 | Safe and Effective Whole Blood ID/AST Device for Use in Neonatal ICU Settings2R44HD084033-04 | GAU, VINCENT JEN-JR | GENEFLUIDICS, INC., CA | $966,760 | ZRG1 |
| 2019 | A Novel Probiotic for the Treatment of Sjogren's Syndrome2R44DE026379-02 | FANGER, GARY | RISE THERAPEUTICS, LLC, MD | $956,644 | ZRG1 |
| 2019 | Product Development of Intensity Modulation for Bolus Electron Conformal Therapy2R44CA199838-02 | ERHART, KEVIN JAMES | DECIMAL, INC., FL | $940,905 | ZRG1 |
| 2019 | An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.2R44CA210696-02 | HUNEKE, RICHARD BRIANLAUB, GLENN W | TDL INNOVATIONS, LLC, NJ | $930,483 | ZRG1 |
| 2019 | PIC1 pre-clinical formulation and optimization as a novel anti-inflammatory pharmacological agent2R44AI131764-02A1 | KRISHNA, NEEL KUMAR | REALTA LIFE SCIENCES, INC., VA | $919,171 | ZRG1 |
| 2019 | Targeting Irritable Bowel Syndrome (IBS) with astressins2R44DK116362-02 | BEHAN, DOMINICLARAUCHE, MURIELRIVIER, JEAN E | SENTIA MEDICAL SCIENCES, INC., CA | $906,525 | ZRG1 |
| 2019 | Protein therapeutic to facilitate healing of chronic wounds.2R44GM123887-02 | TAN, TAO | TRIM-EDICINE, INC., OH | $898,170 | ZRG1 |
| 2019 | Development of MTX-211 for the Treatment of KRAS Mutant Colorectal Cancer2R44CA213715-02 | LEOPOLD, JUDITH SWHITEHEAD, CHRISTOPHER EMIL | MEKANISTIC THERAPEUTICS, LLC, MI | $888,572 | ZRG1 |
| 2019 | A therapeutic vaccine for chronic hepatitis B2R44AI088919-06A1 | MILICH, DAVID R. | VLP BIOTECH, INC., CA | $878,409 | ZRG1 |
| 2019 | A user-friendly point-of-care device for G6PDH determination2R44AI129057-02A1 | HARPER, ROBERT | ANALYTICAL DIAGNOSTIC SOLUTIONS, INC., NJ | $873,090 | ZRG1 |
| 2019 | IND-enabling preclinical development of a sustained-release Pritelivir intravaginal ring for the treatment and prophylaxis of Genital Herpes in women2R44AI136201-02A1 | SMITH, THOMAS J. | AURITEC PHARMACEUTICALS, INC., CA | $860,561 | ZRG1 |
| 2019 | An Interactive, Patient-Specific Virtual Surgical Planning System for Upper Airway Obstruction Treatments2R44EB023121-02 | ENQUOBAHRIE, ANDINET ASMAMAW | KITWARE, INC., NY | $849,999 | ZRG1 |
| 2019 | Renalase: Development as an Innovative New Drug for Acute Pancreatitis2R44DK111251-02A1 | BERKOWITZ, BARRY ADESIR, GARY V. | BESSOR PHARMA, LLC, MA | $849,303 | ZRG1 |
| 2019 | Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses2R44AI118017-03 | CLEMENTS, DAVID E | HAWAII BIOTECH, INC., HI | $839,920 | ZRG1 |
| 2019 | Ice-free vitrification and nanowarming of large osteochondral grafts for transplantation2R44AR073136-02 | BROCKBANK, KELVIN G.M. | TISSUE TESTING TECHNOLOGIES, LLC, SC | $838,363 | ZRG1 |
| 2019 | Patient/Resident Mobility Tracker (PREEMPT)2R44NR015934-02 | CLARK, BRIAN R | BARRON ASSOCIATES, INC., VA | $825,939 | ZRG1 |
| 2019 | Development of A Topical siRNA Therapy to Promote Burn Wound Healing via Depletion of the Novel Microtubule Regulatory, Fidgetin-Like-22R44AR070696-02A1 | DEY, ABHINAVSHARP, DAVID JAMES | MICROCURES, INC., CA | $823,988 | ZRG1 |
| 2019 | Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer1R44CA247503-01 | RISDON, GRANT HWU, JENNIFER D | CANCURE, LLC, WA | $818,940 | ZRG1 |
| 2019 | Stabilization of the RNA Complement of Enveloped Viruses: Beta Testing and Manufacturing Scale-up of a Novel Filter Paper Product for the Field Collection of Dried Blood Spots2R44AI132032-03 | NASARABADI, SHANAVAZ | GENTEGRA, LLC, CA | $817,026 | ZRG1 |
| 2019 | An Ultra-fast Cooling Device for Vitrification and Cryopreservation of Cells and Tissues2R44OD020163-02A1 | HAN, XU | CRYOCRATE, LLC, MO | $815,083 | ZRG1 |
| 2019 | Developing a systems biology platform for predicting, preventing, and treating drug side effects2R44GM121117-02 | BORDBAR, AARASH | SINOPIA BIOSCIENCES, INC., CA | $802,538 | ZRG1 |
| 2019 | Nucleation Enhanced Crystallization of Pharmaceuticals in Continuous Flow Manufacturing to Mitigate Therapeutic Drug Shortages2R44TR001380-02A1 | BOND, ANDREW H. | DENOVX, LLC, IL | $800,139 | ZRG1 |
| 2019 | First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer2R44CA217400-02 | SIGALOV, ALEXANDER B | SIGNABLOK, INC., MA | $799,560 | ZRG1 |
| 2019 | Targeting the Unfolded Protein Response to Treat Retinitis Pigmentosa2R44EY026370-02 | KEENAN, RICHARD MCCULLOCH | OPTIKIRA, LLC, OH | $795,163 | ZRG1 |
| 2019 | SBIR Phase II: Protein A Membrane Columns for Rapid Protein Purification2R44GM125429-02 | ZHOU, JINXIANG | PURILOGICS, LLC, SC | $792,607 | ZRG1 |
| 2019 | Development of a Next Generation Visual Performance Assessment System for Rodents2R44EY025913-02 | CHEN, DONG FENGLUO, GANGXIE, XINMIN SIMON | AFASCI, INC., CA | $788,405 | ZRG1 |
| 2019 | Wireless System for Ambulatory Rodents to Measure Pressure and Volume in the Left Ventricle2R44HL132705-02A1 | RIEHLE, TIMOTHY H. | KORONIS BIOMEDICAL TECHNOLOGIES CORPORAT, MN | $781,601 | ZRG1 |
| 2019 | A CLOSED SYSTEM FOR PATHOGEN REDUCTION OF RED BLOOD CELLS FOR TRANSFUSION1R44HL145783-01 | TABATADZE, DAVID R | ZATA PHARMACEUTICALS, INC., MA | $780,492 | ZRG1 |
| 2019 | Augmented Reality System for the Education of Clinical Caregivers of Older Adults2R44AG057257-02 | BECKER, ADAM | INNOVATIVE DESIGN LABS, INC., MN | $779,815 | ZRG1 |
| 2019 | Chromatography-Free Antibody Purification by Affinity-Phase Separation2R44GM128557-02 | LUGINBUHL, KELLI MICHELLE | ISOLERE BIO, INC., NC | $778,207 | ZRG1 |
| 2019 | Compensation-Free, Highly Multiplexed Flow Cytometer2R44GM123906-02A1 | VACCA, GIACOMO | KINETIC RIVER CORPORATION, CA | $774,933 | ZRG1 |
| 2019 | Bioresorbable Nanoparticles for Visual Detection of Early-Stage Dental Caries2R44DE027903-02 | BLOEMBERGEN, STEVEN | GREENMARK BIOMEDICAL, INC., MI | $770,105 | ZRG1 |
| 2019 | Selection & Optimization of a Therapeutic Protein for Acute Ischemic Stroke Functional Recovery1R44NS107152-01A1 | ADKISSON, HUSTON DAVIS | STREAM BIOMEDICAL, INC., TX | $767,588 | ZRG1 |
| 2019 | Fast, flexible, and economical system for affinity-tag protein purification and tag removal2R44GM126676-02 | BRYAN, PHILIP N | POTOMAC AFFINITY PROTEINS, LLC, MD | $760,681 | ZRG1 |
| 2019 | Next-generation phenotypic antimicrobial susceptibility test platform: rapid results and comprehensive menus2R44AI136125-02 | STERN, ERIC | SELUX DIAGNOSTICS, INC., MA | $760,449 | ZRG1 |
| 2019 | High Throughput Screening of Pharmaceuticals Targeting Heart Cell Contractile Function2R44HL137603-02A1 | PALMER, BRADLEY M | IONOPTIX, LLC, MA | $754,124 | ZRG1 |
| 2019 | An automated test for gestational diabetes based on glycated CD591R44DK124056-01 | PACHECO, CHRIS | MELLITUS, LLC, MA | $750,632 | ZRG1 |
Showing the 200 most recent of 4,393 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.